DeCODE genetics

deCODE genetics (Icelandic: Íslensk erfðagreining) is a biopharmaceutical company based in Reykjavík, Iceland and founded in 1996 by Kári Stefánsson. Its aim was to use population-level genetics studies to identify variations in the human genome associated with common diseases, and to apply these discoveries to treat and prevent them.

As of 2019, more than two-thirds of Iceland's adult population was participating in the company's research efforts. Today, their "population approach" serves as a model for large-scale precision medicine and national genome projects around the world. deCODE is probably best known for its discoveries in human genetics, published in major scientific journals and widely reported in international media. It has also made pioneering contributions to the broad realization of precision medicine, through public engagement in large-scale scientific research; the development of genetic disease risk testing for individuals and across health systems; and new models of private sector participation and partnership in basic science and public health research.

Since 2012, it has been an independent subsidiary of Amgen. Its capabilities and discoveries have directly contributed to the development of novel drugs. Their example has helped spur investment in genomics and precision therapeutics by other pharmaceutical and biotechnology companies.